Skip to main content
. 2021 Nov 9;97(19):e1870–e1885. doi: 10.1212/WNL.0000000000012753

Table 3.

Characteristics of COVID-19 Severity Outcomes, Anti-CD20 DMTs vs All Other DMTs, and Anti-CD20 DMTs vs Natalizumab, Suspected Plus Confirmed COVID-19

graphic file with name NEUROLOGY2021171409T3.jpg